WCM
AZN icon

Westend Capital Management’s AstraZeneca AZN Stock Holding History

Westend Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-117
Closed -$21.5K – 257
2025
Q4 		$21.5K Hold
117
– – 0.01% 117
2025
Q3 		$18K Buy
117
+39
+50% +$5.9K 0.01% 108
2025
Q2 		$10.8K Buy
+78
New +$10.9K ﹤0.01% 127

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

Westend Capital Management's AZN Position: Q1 2026 in Review

Westend Capital Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 117 shares — an estimated $21.5K sold.

Westend Capital Management first reported a position in AZN in Q2 2025 and held it in 3 quarters. The position peaked at $21.5K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Westend Capital Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Westend Capital Management sold 117 AstraZeneca shares in Q1 2026, an estimated $21.5K.
  • Westend Capital Management first reported a position in AstraZeneca in Q2 2025 and held it in 3 quarters.
  • Westend Capital Management's AstraZeneca position peaked at $21.5K in Q4 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Westend Capital Management's 13F filing for Q1 2026, filed 14 Apr 2026.